







2nd Annual "Knowledge Translation to Policy" Day

Cardiovascular Research & Personalized Medicine



May 13, 2011
The Estates of Sunnybrook, Vaughan Estate
Toronto, Ontario







Programme

Purpose

To share research knowledge – developed by the Toronto Health Economics and Technology Assessment Collaborative with the support of the Ontario Ministry of Health and Long-Term Care – with policy makers, funders, healthcare service planners and providers, researchers, and consumers.

8:15 – 9:00 am	Breakfast & registration, Courtyard Ballroom, Vaughan Estate
9:00 – 9:15 am	Welcome, Purpose & Overview Murray Krahn Director, THETA; F. Norman Hughes Chair, Faculty of Pharmacy; Professor,
	University of Toronto

Cardiovascular Research

9:15 – 9:45 am	Heart Failure Clinics Field Evaluation Harindra Wijeysundera Cardiologist, Sunnybrook Health Sciences Centre
9:45 – 10:30 am	Relative Cost-effectiveness of Five Non-invasive Cardiac Imaging Technologies for Diagnosing Coronary Artery Disease in Ontario Gabrielle van der Velde Research Associate, THETA; Adjunct Scientist, Institute for Work and Health
10:30 – 10:45 am	BREAK
10:45 – 11:30 am	Adherence to Quality Indicator Benchmarks and Impact on Coronary Heart Disease Mortality Harindra Wijeysundera Cardiologist, Sunnybrook Health Sciences Centre
11:30 – 12:00 pm	Response Panel Discussion Ben Chan President & CEO, Health Quality Ontario Kori Kingsbury CEO, Cardiac Care Network of Ontario Sacha Bhatia Cardiology Resident, The University of Toronto Division of Cardiology

12:00 – 1:00 pm LUNCH, Courtyard Patio

Programme

Personalized Medicine

1:00 – 1:10 pm	Overview of the Afternoon Murray Krahn
1:10 – 1:30 pm	Introduction to Personalized Medicine Elizabeth Eisenhauer Director, IND Program, NCIC Clinical Trials Group
1:30 – 2:00 pm	Cost-Effectiveness of Oncotype DX Guided Treatment in Early Breast Cancer Mike Paulden Research Associate, THETA Collaborative
2:00 – 2:30 pm	Cost-Effectiveness of KRAS Genetic Testing for Anti-EGFR Treatment Decisions in Metastatic Colorectal Cancer Luciano Ieraci Research Associate, THETA Collaborative
2:30 – 2:45 pm	BREAK
2:45 – 3:15 pm	Cost-Effectiveness of Using EGFR Gene Mutation Testing to Guide the Selection of First- Line Therapy for Patients with Advanced Non-Small Cell Lung Cancer in Ontario Wendong Chen Health Economist, THETA Collaborative
3:15 – 3:55 pm	Response Panel Discussion Elizabeth Eisenhauer Director, IND Program, NCIC Clinical Trials Group Fiona Miller Associate Professor, HPME, University of Toronto
3:55 – 4:00 pm	Closing Remarks Murray Krahn